Apollomics announces vebreltinib data at the 2024 ASCO meeting

Apollomics announced a poster presentation and an oral presentation by partner company, Avistone Biotechnology, at the 2024 American Society of Clinical Oncology, ASCO, Annual Meeting, being held May 31-June 4, 2024, in Chicago, Ill. and virtually. The poster presentation, titled “Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG”, demonstrated vebreltinib consistently showed promising efficacy and favorable safety in NSCLC patients with MET exon 14-skipping mutations. The primary endpoint was overall response rate and was assessed by blinded independent review committee. Per BIRC assessment, the ORR was at 75%, and subgroup analyses showed the ORR was 100.0%, 66.7%, 85.7% and 100.0% among patients with any baseline brain metastases, patients with any baseline liver metastases, patients aged 75 years and older and patients with co-occurring of MET amplification (N=12), respectively. Other efficacy parameters included disease control rate of 96.2%, the median duration of response of 16.5 months, the median time to response of 1.0 month and the median progression-free survival of 14.3 months. Furthermore, the median overall survival was 20.3 months. The 3-year OS rate was 35.1%. No new safety signals were reported with long-term vebreltinib treatment. The oral presentation, titled “Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe: The primary endpoint was overall survival and, after a median follow-up of 4.44 months, the median OS in the vebreltinib group and chemotherapy group were statistically significant at 6.31 months and 3.38 months, respectively. The secondary endpoints were progression-free survival and objective response rate; the median PFS in the vebreltinib group and chemotherapy group were also statistically significant at 1.87 months and 1.05 months, respectively. No significant differences were observed in ORR for the vebreltinib group and chemotherapy group.